Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis
Ustekinumab-aekn (SELARSDI; Alvotech and Teva Pharmaceuticals) has been approved by the FDA as a biosimilar to ustekinumab (Stelara; Johnson & Johnson) to treat moderate to severe plaque psoriasis, as well as active psoriatic arthritis, in adults and …